Evidence map›Paper›PMID 40343305›Full record

ArticleRSC advances2025

Synthesis, molecular docking, and

Loai Saadah, Ghina'a Abu Deiab, Qosay Al-Balas, Iman Basheti

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Loai SaadahFaculty of Pharmacy, Applied Science Private University 11937 Amman Jordan l_saadah@asu.edu.jo +962798222044.ORCID https://orcid.org/0000-0003-1274-777X
Ghina'a Abu DeiabFaculty of Pharmacy, Yarmouk University 21163 Irbid Jordan ghinaadeiab@gmail.com +962791101303.ORCID https://orcid.org/0000-0002-9398-6141
Qosay Al-BalasFaculty of Pharmacy, Jordan University for Science & Technology 22110 Irbid Jordan qabalas@just.edu.jo +962776337216.ORCID https://orcid.org/0000-0002-8350-900X
Iman BashetiFaculty of Pharmacy, Jadara University 21110 Irbid Jordan i.basheti@jadara.edu.jo +962797708060.ORCID https://orcid.org/0000-0002-8460-1158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a validated commonly studied in the pathology of several diseases, including novel coronavirus and breast cancer. Herein, we report the synthesis, molecular docking, and validation of a novel ACE2 inhibitor that was previously discovered by our team based on diverse scaffolds of other ACE2 inhibitors and carnosine. The synthesized 4-subsitituted imidazole compound, namely, LMS1007, was characterized through

Identifiers

PMID40343305
PMCPMC12060149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.